Navigation Links
Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Date:2/12/2008

CORONA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for silodosin, a novel alpha(1)- adrenoreceptor antagonist, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Watson is seeking marketing approval of silodosin from the FDA for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate. Watson anticipates that the FDA will take action on its application in the fourth quarter 2008.

Silodosin was designed to decrease urinary resistance and improve dysuria (difficulty or pain in urination) associated with BPH. In clinical trials, silodosin demonstrated a very low level of the most highly-reported cardiovascular and blood pressure-related side effects associated with existing BPH treatments, including dizziness and first-dose syncope (fainting).

"This filing highlights Watson's capabilities in new drug development and our commitment to this product, providing solutions to the millions of men with BPH symptoms," said Paul Bisaro, Watson's President and Chief Executive Officer. "Watson is expanding the portfolio it offers to urologists and their patients, focusing on symptom management that makes a big difference in their day-to-day lives."

Watson submitted the filing for silodosin with data from two Phase 3 multi-center (88 sites), randomized, double-blind, placebo-controlled trials that evaluated a total of 923 patients with signs and symptoms of BPH for 12 weeks. The trials demonstrated that a once daily 8mg dose of silodosin given for 12 weeks provided significant relief of BPH symptoms, compared with place
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
2. Watson Launches Generic Biaxin(R) XL
3. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
6. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
7. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
8. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
9. Inverseon Announces Positive Phase IIa Asthma Study
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... YORK , Sept. 19, 2014 Harwood ... against the board of directors of PDL BioPharma, Inc. ... concerning whether the board has breached its fiduciary duties ... On September 16, 2014, the Company disclosed: "On ... independent registered accounting firm, Ernst & Young LLP ("EY"), ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 /PRNewswire-USNewswire/ ... often used to inflate sales of brand drugs ... Part D,  according to a new report ... Services Office of the Inspector General (OIG). Federal anti-kickback ... sales of goods that are subsidized by the ...
(Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic ... Inc. announced today that the first patient has ... a small molecule Stem Cell Modulator (SCM) designed to increase ... of key pathways that guide cell fate. The study, ...
... W.Va., May 27 The Blanchette Rockefeller Neurosciences ... NYSE: IMA ) of Waltham, Massachusetts, a ... announced today that they will work together to ... Alzheimer,s disease first discovered by scientists at BRNI. ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 2Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 3Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 4
(Date:9/21/2014)... Discount-Dress.com, a company that specializes in fashion garments ... implement a new shopping cart software on its website. ... Furthermore, the company has unveiled a new collection of ... items come in fashionable designs; all of them are ... off. "We are happy to release the new beach ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 ... Fenofibrate (CAS 49562-28-9) Industry, 2009-2019 is a ... and Chinese Fenofibrate (CAS 49562-28-9) industry. The ... Fenofibrate (CAS 49562-28-9) including its classification, application ... and China’s top manufacturers of Fenofibrate (CAS ...
(Date:9/21/2014)... Rio, Colorado (PRWEB) September 21, 2014 ... Colorado, ten teams of disabled and able-bodied athletes rafted ... and completed a ropes course in pursuit of outdoor ... from national non-profit World T.E.A.M. Sports, disabilities proved ... athletes who successfully completed the three stage event. , ...
(Date:9/21/2014)... An experienced review website in the global market, Top10BestSEOHosting.com, ... announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), GoDaddy and Bluehost ... has been a boom in websites in recent years, ... in the number of web hosting companies that offer ... VPS (Virtual Private Server) is the method of partitioning ...
(Date:9/21/2014)... Recently, BambooIndustry.com, an experienced producer of natural bamboo ... panels ( http://www.bambooindustry.com/products/bamboo-panel/ ). The company’s excellent panels are ... available at discounted prices now, from 10 to 30 ... panels are available in many specifications; they are ... them is finely manufactured by qualified workers. They are ...
Breaking Medicine News(10 mins):Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2
... News) -- Many seniors may be at increased risk for ... treat thyroid problems, a new study says. The findings ... elderly patients with thyroid problems and that regular dose monitoring ... said. Reporting in the online April 28 edition of ...
... THURSDAY, April 28 (HealthDay News) -- Rising rates of ... cause for concern because excess weight is associated with ... In people with arthritis, obesity is associated with ... total joint replacement and poor outcomes after joint replacement. ...
... THURSDAY, April 28 (HealthDay News) -- Memory in monkeys and ... says. Experiments with rhesus monkeys showed that, like people, ... ability to identify something when you see it. Recall is ... study appears online April 28 in the journal Current ...
... News) -- Your social status affects how your brain ... the new study, brain activity in volunteers was measured ... increased brain activity when shown information about others at ... had greater response to others like them, the investigators ...
... which combines interval training and healthy eating practices seems ... according to the results of a new study from ... physical activity (PIC Centre). Results of the study were ... in Montreal. Within the framework of this study, ...
... oncologist practiced were two factors that strongly influenced the choice ... to an article published April 29 online in the ... IMRT and the cost of radiation therapy increased sharply over ... delivery technique that modulates the radiation beams to conform to ...
Cached Medicine News:Health News:Thyroid Drugs May Raise Fracture Risk in Elderly 2Health News:Rising Obesity Rates Add to Arthritis Woes in U.S. 2Health News:Shared Social Status Boosts Brain Activity, Research Shows 2Health News:Obesity: Conclusive results for the Montreal Heart Institute's EPIC Centre Kilo-Actif program 2Health News:Use of costly breast cancer therapy strongly influenced by reimbursement policy 2